

Protein Innovation for Healthcare

Protéus supports the continuous growth of biopharmaceuticals by providing opportunities to accelerate R&D programs, whether for princeps drugs or biosimilars

For more than 10 years, Protéus has been working on proteins from the most diverse origins. This outstanding know-how in recombinant expression in micro-organisms and process development has enabled the Company to create Prod'line™, a comprehensive platform of services to address recombinant protein expression challenges.

Protéus provides services dedicated to the rapid identification of optimal expression conditions by testing in parallel a broad range of parameters such as hosts, constructs, temperature, induction, tags, intra-cellular, periplasmic or secreted expression, or helpers. Our aim is at obtaining properly folded and functional proteins using scalable processes. Panels of multi-host and single host expression profiling are available. We also provide customized versions of this service that are based on our client's preferred expression hosts, as well as downstream processing, including concentration and purification.

“OUR AIM IS
AT OBTAINING
PROPERLY FOLDED
AND FUNCTIONAL
PROTEINS USING
SCALABLE
PROCESSES”

**WE HELP MEETING
TODAY'S INDUSTRIAL,
ENERGETIC
AND ENVIRONMENTAL
CHALLENGES**

Most recently, in collaboration with the life science department of French CEA (atomic energy agency), we created a new Immuno'line™ immunogenicity management service. Protéus has leveraged the 10-year experience of the CEA to build robust and high performance human immunogenicity testing services. Our technology enables to rank proteins or variants of proteins according to their immunogenicity.

Applications include batch-to-batch or plant-to-plant QC, preclinical immunogenicity assessment and identification of immunogenic sequences.

The Company has created a dedicated business unit to better serve the biotech and pharmaceutical industry with this comprehensive protein-related services platform. Visit our dedicated website (www.proteus-psi.com) to know more.

Protein Innovation for Healthcare

Application includes expression of biomarkers identified in post-genomic studies, soluble expression of difficult-to-express proteins, inclusion bodies refolding processes, expression of toxic proteins, labeled proteins (heavy-isotopes or radio-isotopes), therapeutic proteins and production of antigens required for antibody production.


Proteus also offers outstanding opportunities to create new industrial property by developing tailor-made proteins. Dramatic improvements can be provided in key parameters such as activity, selectivity, efficiency, side effects, solubility, stability, half-life, immunogenicity and production costs. Based on our proprietary EvoSight™ and L-Shuffling™ technologies for protein engineering and gene shuffling, we created the Dream'line™ services to prepare high performance proteins that are optimized for their application.

CASE STUDY

Call for more
information

www.proteus-psi.com

CASE STUDY: IMMUNOGENICITY ASSESSMENT OF BIOLOGICAL DRUG CANDIDATES VS CLINICAL REFERENCES



Immuno'line™ assays enable an accurate evaluation and ranking of both T cell response intensity and immunoprevalence (responder frequency) of your biologics. Immuno'line results can be compared to clinical references, hence enabling immunogenic risk management throughout the drug development cycle. KLH and OVA (ovalbumin) were used in this example as clinical references to rank new candidates for their immunogenicity.

proteus

